Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $20.19 Consensus PT from Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been assigned a consensus rating of “Hold” from the twenty-three brokerages that are currently covering the stock, Marketbeat reports. Four analysts have rated the stock with a sell rating, nine have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $20.1875.

NTLA has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Friday, July 17th. Wolfe Research downgraded Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price for the company. in a research note on Wednesday, July 15th. Citizens Jmp reissued a “market outperform” rating and issued a $30.00 target price on shares of Intellia Therapeutics in a report on Monday, June 15th. Leerink Partners set a $35.00 price target on shares of Intellia Therapeutics in a research note on Monday, April 27th. Finally, The Goldman Sachs Group lifted their price target on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a report on Tuesday, April 28th.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $10.97 on Monday. The firm has a 50 day simple moving average of $13.74 and a two-hundred day simple moving average of $13.49. Intellia Therapeutics has a one year low of $7.95 and a one year high of $28.25. The company has a market cap of $1.53 billion, a P/E ratio of -3.10 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The firm had revenue of $15.05 million for the quarter, compared to the consensus estimate of $13.81 million. During the same quarter last year, the business posted ($1.10) EPS. On average, analysts expect that Intellia Therapeutics will post -3.18 earnings per share for the current fiscal year.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 4,677 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the sale, the executive vice president owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. The trade was a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the transaction, the chief accounting officer owned 66,886 shares of the company’s stock, valued at $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. grew its position in Intellia Therapeutics by 38.0% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 220,523 shares of the company’s stock worth $3,731,000 after acquiring an additional 60,720 shares during the last quarter. Seven Fleet Capital Management LP bought a new position in Intellia Therapeutics in the first quarter valued at about $404,000. Avidity Partners Management LP bought a new position in Intellia Therapeutics in the first quarter valued at about $962,000. Wellington Grp LLC boosted its stake in shares of Intellia Therapeutics by 50.9% during the first quarter. Wellington Grp LLC now owns 46,297 shares of the company’s stock valued at $594,000 after purchasing an additional 15,620 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Intellia Therapeutics by 11.2% during the first quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock valued at $17,713,000 after purchasing an additional 139,325 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.